Table 2 Univariate and multivariate analysis

Group

 MMP3 and pIGF1R−

Reference

Reference

Reference

Reference

 MMP3 or pIGF1R+

1.39 (0.71–2.72)

1.10 (0.52–2.17)

1.53 (0.76–3.06)

1.67 (0.77–3.65)

0.20

 Albumin >median

0.73 (0.44–1.23)

0.82 (0.47–1.44)

 Leucocytes >median

1.16 (0.73–1.85)

1.50 (0.90–2.49)

 LDH >median

1.36 (0.84–2.21)

1.50 (0.89–2.55)

 Age

0.99 (0.97–1.00)

0.99 (0.98–1.01)

Kit mutation

 Exon 11/13

0.46 (0.28–0.76)

0.71 (0.41–1.21)

0.57 (0.33–0.97)

 Other

Reference

Reference

ECOG

 PS 0

Reference

Reference

Reference

Reference

 PS 1

1.13 (0.67–1.8)

1.17 (0.66–2.07)

1.74 (0.99–3.07)

2.00 (1.08–3.67)

0.026

 PS > 1

1.64 (0.73–3.68)

2.05 (0.88–4.76)

4.45 (1.85–10.76)

5.25 (2.08–13.26)

0.0005

 Female

1.02 (0.64–1.63)

1.01 (0.61–1.67)

Primary site

 Stomach

1.61 (1.00–2.59)

1.36 (0.82–2.27)

 Others

Reference

Reference

Extension of disease

Ta

 1 metastatic organ

Reference

Reference

Reference

Reference

 2 or more metastatic organs

2.59 (1.52–4.42)

2.56 (1.46–4.52)

1.84 (1.03–3.27)

1.93 (1.03–3.62)

0.041

Surgery primary tumor

 Yes

Reference

Reference

 No

1.19 (0.51–2.75)

0.75 (0.27–2.08)

0.26 (0.09–0.76)

0.014

Disease-free interval

 <24 months

13.4 (6.93–25.77)

6.61 (3.72–11.79)

18.87 (8.54–41.73)

16.73 (7.97–35.13)

<0.0001

 ≥24 months

Reference

Reference

Reference

Reference